2020 top stories in kidney cancer

This article summarises the key breakthroughs in the treatment of renal cell carcinoma (RCC) in 2020, including a new first-line VEGF-TKI and immunotherapy combination (cabozantinib plus nivolumab) and immunotherapy as a new standard of treatment for patients with non−clear cell RCC and sarcomatoid RCC. Read more in Practice Update here Watch a video interview on […]

read more

Individualising first line treatment for advanced kidney cancer

In recent years, a number of new, effective treatments have become available for advanced kidney cancer. However, with more drugs available it has become more difficult to decide which drugs to choose for particular patients, and in which order to use them. In addition, the new treatments do not work for all patients and they […]

read more

Pembrolizumab plus lenvatinib for first-line treatment of kidney cancer shows promise

Results from the phase 3 KEYNOTE-581/CLEAR trial show that the combination of pembrolizumab plus lenvatinib significantly improved the time taken for the cancer to start growing again (progression-free survival), overall survival, and the response rate compared with sunitinib, when used for untreated patients with advanced renal cell carcinoma (RCC). The pembrolizumab/lenvatinib combination had similar side […]

read more

Approach to selection of first-line treatment for advanced kidney cancer

During this online interview, the approach to selection of first-line treatment for patients with metastatic renal cell carcinoma (RCC) was discussed.  Traditionally, the selection of initial treatments was very straightforward, and patients were treated with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors, (TKIs) such as sunitinib and pazopanib. Over the past 2 years, decisions […]

read more

Managing adverse events in kidney cancer patients on immunotherapy/TKI combination treatment

In this video interview, Dr Eric Jonasch from MD Anderson Cancer Center, Texas in the USA talks about managing adverse events to immunotherapy and targeted therapy combinations. There are more adverse events from any type of combination treatment compared to single treatments, especially immune adverse events. Nivolumab alone is very well tolerated and quite easy […]

read more

Cabozantinib plus atezolizumab for non-clear cell kidney cancer

In this video interview, Dr Monty Pal from the City of Hope Hospital in California talks about a subset of patients in the COSMIC-021 (cohort 10) with non-clear cell RCC, such as papillary renal cell carcinoma (RCC) and chromophobe RCC. Response rates exceeded 30%, which are very promising findings compared to TKIs alone. However, not […]

read more

Managing immune-related adverse events

In these video interviews, Dr Eric Jonasch from MD Anderson Cancer Center in Texas and Dr Monty Pal from the City of Hope Hospital in California talk about immune-related adverse events in people with advanced kidney cancer taking combination therapies and immunotherapy: Managing Adverse Events Among RCC Patients Receiving Combination Treatment With Targeted Therapy and […]

read more

Lenvatinib plus everolimus for non clear cell kidney cancer

Treating non-clear cell renal cell carcinoma (RCC) is challenging because these diseases are rare, and so far there are no effective treatments for this group of patients. Non-clear cell RCC is currently treated in a similar way to clear cell RCC. In a phase 2 clinical trial, 31 patients with non-clear cell RCC were treated […]

read more

PDIGREE trial: Ipilimumab plus nivolumab with cabozantinib for untreated advanced kidney cancer

During this video interview from UroToday, Dr Tian Zhang from the Duke Cancer Centre in North Carolina, USA talks about the PDIGREE trial and the effect of the COVID-19 pandemic on the trial. PDIGREE is a novel adaptive study which will help answer many important questions, such as treatment duration, when to use vascular endothelial […]

read more

Cabozantinib plus atezolizumab combination for advanced kidney cancer

In this study, two doses of cabozantinib were tested in combination with atezolizumab for untreated advanced renal cell carcinoma (RCC). Cabozantinib is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI), while atezolizumab is an immune checkpoint inhibitor.  Two doses of cabozantinib were tested; 40 mg and 60 mg. The data were fairly comparable […]

read more
Showing 21 to 30 of 133 results
  TOP